Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

Show other versions (1)

<h4>Background</h4> <p>Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor (PI) plus raltegravir (RAL) as an alternative second-line c...

Full description

Bibliographic Details
Main Authors: Hakim, J, Thompson, J, Kityo, C, Hoppe, A, Kambugu, A, van Oosterhout, J, Lugemwa, A, Siika, A, Mwebaze, R, Mweemba, A, Abongomera, G, Thomason, M, Easterbrook, P, Mugyenyi, P, Walker, A, Paton, N
Format: Journal article
Published: Elsevier 2017

Similar Items